Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cenegermin - Dompe Farmaceutici

Next Previous
Drug Profile

Cenegermin - Dompe Farmaceutici

Alternative Names: Cenegermin-bkbj; Nerve growth factor - Anabasis/Dompe; Ophtha-NGF; Ophtha-NGF Intravitreal; Oxervate; rhNGF; Sentinel

Latest Information Update: 29 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anabasis Pharma
  • Developer Anabasis Pharma; Dompe Farmaceutici; Ospedale San Raffaele
  • Class Anti-inflammatories; Antiglaucomas; Eye disorder therapies; Nerve growth factors; Neuroprotectants; Proteins
  • Mechanism of Action Nerve growth factor receptor agonists; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratitis; Retinitis pigmentosa
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Keratitis
  • Phase III Dry eyes
  • Phase II Glaucoma; Ischaemic optic neuropathy; Retinitis pigmentosa
  • Phase I Eye disorders

Most Recent Events

  • 28 Nov 2025 Dompe' Farmaceutici plans a phase II trial for Cerebral Palsy (In children, In adolescents, In infants, In neonates) in Italy (Intranasal) (CTIS2025-522786-29-00)
  • 17 Oct 2025 Phase-II clinical trials in Ischaemic-optic-neuropathy (Intranasal) (Dompe Farmaceutici pipeline; October 2025)
  • 17 Oct 2025 Cenegermin receives US FDA Commissioner's National Priority Voucher Program for Ischaemic-optic-neuropathy in USA (Intranasal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top